{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:45:54Z","timestamp":1787060754589,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Venous thromboembolism (VTE) is the third most common cardiovascular disease and optimizing treatment is essential. In this single-center pilot study, we sought to investigate the effects of statins in addition to anticoagulation in patients with acute VTE. We enrolled patients over 18 with an acute proximal lower extremity deep vein thrombosis with or without pulmonary embolism. Patients were randomized to anticoagulation alone (with either warfarin or rivaroxaban) or anticoagulation and atorvastatin 40\u200amg daily and followed for 9 months. The primary objective was to determine if adjunct atorvastatin reduced thrombin generation, measured by endogenous thrombin potential and\/or peak thrombin concentration. Secondary endpoints included recurrent VTE, arterial thrombosis, bleeding events, lipidomic profiles, and symptoms of post thrombotic syndrome. A total of 21 patients were enrolled (11 anticoagulation only and 10 anticoagulation and atorvastatin) over 3.5 years. Endogenous thrombin potential or peak thrombin was not significantly recued with the addition of atorvastatin. Atorvastatin did significantly reduce the mean LDLs at 3 months, without reduction of either\n                      <jats:sc>d<\/jats:sc>\n                      -dimer or high-sensitivity-C reactive protein. Given the low recruitment rate, continuation of the study was deemed futile and the study was terminated early. Barriers to enrollment and completion of study included the many ineligible patients by exclusion criteria (e.g., preexisting statin use, active malignancy, etc.) and high rate of lost follow-up. The pilot study was terminated early but could inform obstacles for future studies investigating the effects of statins in the management of patients with VTE.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mbc.0000000000000968","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T23:03:13Z","timestamp":1605567793000},"page":"16-22","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism"],"prefix":"10.1097","volume":"32","author":[{"given":"Tzu-Fei","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda P.","family":"Waller","sequence":"additional","affiliation":[{"name":"Center for Clinical & Translational Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Lin","sequence":"additional","affiliation":[{"name":"College of Food, Agriculture, and Environmental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[{"name":"Center for Biostatistics, The Ohio State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Bartosic","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Riedl","sequence":"additional","affiliation":[{"name":"College of Food, Agriculture, and Environmental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce A.","family":"Kerlin","sequence":"additional","affiliation":[{"name":"Center for Clinical & Translational Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital"},{"name":"Division of Hematology\/Oncology\/Blood and Marrow Transplant, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"R1-20250620","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology","volume":"117","author":"Cushman","year":"2004","journal-title":"Am J Med"},{"key":"R2-20250620","first-page":"611","article-title":"Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism","volume":"31","author":"Stein","year":"2010","journal-title":"Crit Care Clin"},{"key":"R3-20250620","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clinthera.2014.10.024","article-title":"Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States","volume":"37","author":"LaMori","year":"2015","journal-title":"Clin Ther"},{"key":"R4-20250620","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/CIRCULATIONAHA.114.009107","article-title":"30-year mortality after venous thromboembolism: a population-based cohort study","volume":"130","author":"Sogaard","year":"2014","journal-title":"Circulation"},{"key":"R5-20250620","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"R6-20250620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"Prandoni","year":"1996","journal-title":"Ann Intern Med"},{"key":"R7-20250620","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1538-7836.2008.03002.x","article-title":"Determinants of health-related quality of life during the 2 years following deep vein thrombosis","volume":"6","author":"Kahn","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R8-20250620","first-page":"968","article-title":"Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation","volume":"23","author":"Adeboyeje","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"R9-20250620","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R10-20250620","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"Ageno","year":"2008","journal-title":"Circulation"},{"key":"R11-20250620","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"R12-20250620","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/archinte.161.11.1405","article-title":"Use of statins and the subsequent development of deep vein thrombosis","volume":"161","author":"Ray","year":"2001","journal-title":"Arch Intern Med"},{"key":"R13-20250620","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1161\/01.CIR.0000019406.74017.B2","article-title":"Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen\/progestin Replacement Study (HERS)","volume":"105","author":"Herrington","year":"2002","journal-title":"Circulation"},{"key":"R14-20250620","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2008.03235.x","article-title":"HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis","volume":"7","author":"Ramcharan","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R15-20250620","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1538-7836.2009.03279.x","article-title":"Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case\u2013control study","volume":"7","author":"Sorensen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R16-20250620","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1160\/TH11-12-0851","article-title":"Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism","volume":"107","author":"Zolcinski","year":"2012","journal-title":"Thromb Haemost"},{"key":"R17-20250620","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2011.05.003","article-title":"Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment","volume":"5","author":"van Kuilenburg","year":"2011","journal-title":"J Clin Lipidol"},{"key":"R18-20250620","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/j.1538-7836.2006.02030.x","article-title":"Why should statins prevent venous thromboembolism? A systematic literature search and a call for action","volume":"4","author":"Squizzato","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R19-20250620","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1016\/j.thromres.2013.04.026","article-title":"Atorvastatin favorably modulates proinflammatory cytokine profile in patients following deep vein thrombosis","volume":"132","author":"Zolcinski","year":"2013","journal-title":"Thromb Res"},{"key":"R20-20250620","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"R21-20250620","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1538-7836.2009.03294.x","article-title":"Definition of postthrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization","volume":"7","author":"Kahn","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R22-20250620","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"R23-20250620","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"R24-20250620","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R25-20250620","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.thromres.2011.10.017","article-title":"Thrombin generation in clinical conditions","volume":"129","author":"Ten Cate","year":"2012","journal-title":"Thromb Res"},{"key":"R26-20250620","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2009.11.012","article-title":"Standardisation of thrombin generation test \u2013 which reference plasma for TGT? An international multicentre study","volume":"125","author":"Dargaud","year":"2010","journal-title":"Thromb Res"},{"key":"R27-20250620","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1681\/ASN.2014111097","article-title":"Disease severity correlates with thrombotic capacity in experimental nephrotic syndrome","volume":"26","author":"Kerlin","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R28-20250620","doi-asserted-by":"crossref","first-page":"e32894","DOI":"10.1371\/journal.pone.0032894","article-title":"Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial","volume":"7","author":"Macchia","year":"2012","journal-title":"PLoS One"},{"key":"R29-20250620","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/jth.14364","article-title":"Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial","volume":"17","author":"Orsi","year":"2019","journal-title":"J Thromb Haemost"},{"key":"R30-20250620","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1185\/030079903125002405","article-title":"Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial","volume":"19","author":"McKenney","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"R31-20250620","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1160\/TH10-12-0810","article-title":"Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease","volume":"106","author":"Mobarrez","year":"2011","journal-title":"Thromb Haemost"},{"key":"R32-20250620","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chemphyslip.2018.05.005","article-title":"Regulation of endogenic metabolites by rosuvastatin in hyperlipidemia patients: an integration of metabolomics and lipidomics","volume":"214","author":"Lee","year":"2018","journal-title":"Chem Phys Lipids"},{"key":"R33-20250620","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11306-010-0207-x","article-title":"Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study","volume":"6","author":"Kaddurah-Daouk","year":"2010","journal-title":"Metabolomics"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T13:03:00Z","timestamp":1750424580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0000000000000968","relation":{},"ISSN":["0957-5235","1473-5733"],"issn-type":[{"value":"0957-5235","type":"print"},{"value":"1473-5733","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}